UKCTOCS更新:将癌症筛查试验延迟效应见解应用于长期随访死亡率分析
UKCTOCS长期随访原计划2020年主分析沿用2014年比例风险Cox模型,但鉴于癌症筛查死亡率效应常延迟,研究者咨询11位专家后8位支持改用允许延迟效应的检验(选项C),最终选用2016年Versatile检验并以Royston-Parmar模型估计5、10、15、18年疾病特异性死亡率绝对差。结论认为基于新证据改变主结局分析设计具有新颖性,亟需就长期随机癌症筛查试验死亡率结局的设计、检验、估计和报告达成共识。
要点
- 癌症筛查试验死亡率效应常延迟,恒定效应模型可能低估长期获益。
- UKCTOCS长期随访主分析改用Versatile检验以兼顾早期、恒定或延迟效应。
- 以Royston-Parmar模型估计5、10、15、18年疾病特异性死亡率绝对差。
核心结论
- 基于新证据和新统计方法改变长期随访主结局分析设计具有新颖性,影响超出UKCTOCS。
- 亟需就长期随机癌症筛查试验死亡率结局的设计、检验、估计和报告达成共识。
研究设计与样本
- UKCTOCS长期随访(LTFU UKCTOCS)主死亡率分析的方法学决策过程。
- 致信12位统计/流行病学/筛查试验专家,11位回复,比较三种随访分析选项。
主要发现
- 11位回复专家中8位支持改用允许潜在延迟效应的检验(选项C),3位支持保留Cox模型(选项A)。
- 最终选用2016年提出的Versatile检验,该检验对早期、恒定或延迟效应均保持良好把握度。
- 保留Royston-Parmar模型估计5、10、15、18年疾病特异性死亡率绝对差。
关键数值与推荐
- 选项A:使用2001-2020全部数据并沿用2014年Cox模型。
- 选项B:仅使用2015-2020新数据。
- 选项C:使用2001-2020全部数据并采用允许延迟效应的检验。
- 最终选择Versatile检验并以Royston-Parmar模型估计5、10、15、18年绝对死亡率差。
临床怎么用
- 长期癌症筛查试验分析死亡率时应预先考虑延迟效应并预先指定相应统计方法。
- 主结局分析方法变更应基于新证据并咨询专家、保持透明报告。
局限性
- 专家咨询意见非正式共识,11位回复中8位支持选项C、3位支持选项A。
- 原文未报告Versatile检验或Royston-Parmar模型的具体数值结果。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND: During trials that span decades, new evidence including progress in statistical methodology, may require revision of original assumptions. An example is the continued use of a constant-effect approach to analyse the mortality reduction which is often delayed in cancer-screening trials. The latter led us to re-examine our approach for the upcoming primary mortality analysis (2020) of long-term follow-up of the United Kingdom Collaborative Trial of Ovarian Cancer Screening (LTFU UKCTOCS), having initially (2014) used the proportional hazards (PH) Cox model. METHODS: We wrote to 12 experts in statistics/epidemiology/screening trials, setting out current evidence, the importance of pre-specification, our previous mortality analysis (2014) and three possible choices for the follow-up analysis (2020) of the mortality outcome: (A) all data (2001-2020) using the Cox model (2014), (B) new data (2015-2020) only and (C) all data (2001-2020) using a test that allows for delayed effects. RESULTS: Of 11 respondents, eight supported changing the 2014 approach to allow for a potential delayed effect (option C), suggesting various tests while three favoured retaining the Cox model (option A). Consequently, we opted for the Versatile test introduced in 2016 which maintains good power for early, constant or delayed effects. We retained the Royston-Parmar model to estimate absolute differences in disease-specific mortality at 5, 10, 15 and 18 years. CONCLUSIONS: The decision to alter the follow-up analysis for the primary outcome on the basis of new evidence and using new statistical methodology for long-term follow-up is novel and has implications beyond UKCTOCS. There is an urgent need for consensus building on how best to design, test, estimate and report mortality outcomes from long-term randomised cancer screening trials. TRIAL REGISTRATION: ISRCTN22488978 . Registered on 6 April 2000.
引用
- Burnell M, Gentry-Maharaj A, Skates SJ, et al. UKCTOCS update: applying insights of delayed effects in cancer screening trials to the long-term follow-up mortality analysis. Trials. 2021. PMID: 33648562. doi:10.1186/s13063-021-05125-8
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。